

TDMs No. 99020 - 05

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 02/11/2009

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

F1_Rev.1_R2

C Number: C99020
Lock Date: 01/06/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.1.0

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1		
Moribund Sacrifice	8	10	12	35
Natural Death	3	7	10	13
Survivors				
Terminal Sacrifice	39	32	28	2
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Perforation		1		
Periesophageal Tissue, Inflammation		1 [2.0]		
Intestine Large, Cecum	(50)	(50)	(49)	(50)
Inflammation			6 [1.2]	21 [1.7]
Mineralization				4 [1.5]
Ulcer				3 [3.0]
Intestine Large, Colon	(50)	(50)	(50)	(50)
Hemorrhage		1 [2.0]		
Inflammation		1 [3.0]	1 [3.0]	1 [1.0]
Parasite Metazoan	1 [1.0]		1	
Ulcer			1 [3.0]	
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Inflammation			1 [1.0]	
Parasite Metazoan	2	1		1
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Diverticulum			1	
Erosion				2 [2.0]
Inflammation			1 [3.0]	1 [2.0]
Ulcer				1 [3.0]
Epithelium, Hyperplasia				1 [2.0]
Intestine Small, Ileum	(50)	(50)	(49)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Peyer's Patch, Hyperplasia	1 [2.0]	1 [3.0]		
Liver	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Angiectasis			1 [2.0]	
Basophilic Focus	36	5	2	2
Bile Stasis				1 [2.0]
Clear Cell Focus	22	22	20	1
Congestion		1 [2.0]		
Eosinophilic Focus	1	2	12	3
Fatty Change	1 [2.0]	10 [1.4]	27 [1.4]	2 [1.0]
Hematopoietic Cell Proliferation			1 [1.0]	
Hepatodiaphragmatic Nodule	6	6	2	3
Inflammation	41 [1.0]	36 [1.0]	41 [1.2]	46 [1.3]
Mixed Cell Focus	9	3	10	1
Pigmentation, Bile		1 [1.0]		
Thrombosis			1 [2.0]	
Arteriole, Inflammation		1 [2.0]		
Bile Duct, Crystals			1 [4.0]	
Bile Duct, Cyst			11 [2.2]	9 [2.1]
Bile Duct, Hyperplasia	29 [1.1]	15 [1.1]	37 [1.5]	50 [3.0]
Centrilobular, Hepatocyte, Degeneration	3 [2.3]		1 [2.0]	
Hepatocyte, Cellular Alteration, Diffuse		2 [2.0]	21 [1.4]	46 [1.8]
Hepatocyte, Degeneration, Cystic	1 [1.0]	1 [1.0]	3 [1.3]	
Hepatocyte, Necrosis		1 [3.0]	6 [1.2]	16 [1.8]
Kupffer Cell, Pigmentation, Hemosiderin			1 [1.0]	
Oval Cell, Hyperplasia			8 [1.3]	44 [1.6]
Portal, Fibrosis	8 [1.0]	6 [1.0]	13 [1.2]	43 [1.5]
Mesentery	(9)	(11)	(11)	(4)
Hemorrhage				1 [3.0]
Inflammation		1 [3.0]		
Mineralization				1 [3.0]
Necrosis	7 [2.9]	9 [2.9]	10 [3.0]	2 [3.0]
Thrombosis				1 [3.0]
Oral Mucosa	(0)	(1)	(3)	(0)
Pharyngeal, Cyst			1 [4.0]	
Pharyngeal, Hyperplasia			1 [4.0]	
Pancreas	(50)	(50)	(50)	(50)
Hemorrhage		1 [2.0]		
Inflammation			1 [2.0]	
Acinus, Atrophy	13 [1.6]	24 [1.4]	20 [1.4]	18 [1.2]
Acinus, Atypia Cellular	1 [1.0]			
Acinus, Hyperplasia	11 [2.2]	8 [1.8]	7 [1.9]	1 [1.0]
Duct, Cyst	4 [1.0]	5 [1.4]	1 [1.0]	5 [1.4]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Salivary Glands	(50)	(49)	(50)	(50)
Atrophy				1 [1.0]
Basophilic Focus	1			
Hyperplasia	1 [2.0]			
Stomach, Forestomach	(50)	(50)	(50)	(50)
Erosion				1 [3.0]
Inflammation	2 [1.5]	4 [1.8]	8 [1.9]	23 [2.1]
Mineralization		1 [2.0]		4 [2.0]
Perforation				5
Ulcer		2 [2.0]	7 [3.1]	16 [3.1]
Epithelium, Hyperplasia	16 [1.3]	21 [1.3]	20 [2.0]	23 [2.3]
Stomach, Glandular	(50)	(50)	(50)	(50)
Erosion			2 [2.5]	
Inflammation	1 [1.0]	3 [1.0]	1 [1.0]	6 [1.2]
Mineralization		1 [2.0]	4 [2.0]	21 [1.7]
Ulcer		1 [4.0]		
Epithelium, Hyperplasia			1 [1.0]	
Serosa, Inflammation				1 [1.0]
Tongue	(0)	(1)	(2)	(0)
Tooth	(0)	(2)	(0)	(0)
Peridontal Tissue, Inflammation		1 [2.0]		
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Dilatation				1 [3.0]
Mineralization			1 [2.0]	24 [2.0]
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	44 [2.4]	44 [2.1]	48 [2.2]	50 [2.2]
Mineralization			1 [3.0]	23 [1.6]
Artery, Inflammation	1 [1.0]			
Atrium, Thrombosis			1 [4.0]	
Endocardium, Bacterium			2	
Endocardium, Inflammation			1 [2.0]	
Valve, Thrombosis		1 [1.0]		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Degeneration, Cystic	1 [1.0]		2 [2.5]	
Hematopoietic Cell Proliferation		1 [1.0]		
Hyperplasia	27 [1.6]	16 [1.4]	23 [1.5]	18 [1.6]
Hypertrophy	11 [1.7]	12 [1.3]	16 [1.6]	9 [1.6]
Vacuolization Cytoplasmic		1 [2.0]	1 [2.0]	
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	22 [1.7]	19 [1.6]	30 [1.9]	31 [1.8]
Infiltration Cellular, Mononuclear Cell		1 [1.0]		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia				1 [2.0]
Parathyroid Gland	(49)	(44)	(45)	(48)
Hyperplasia			3 [2.3]	36 [2.5]
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Angiectasis	2 [2.5]			
Pars Distalis, Cyst	2 [2.5]		1 [3.0]	1 [2.0]
Pars Distalis, Hyperplasia	22 [1.9]	24 [1.6]	18 [1.9]	14 [1.4]
Pars Distalis, Pigmentation	1 [1.0]			
Pars Intermedia, Cyst			1 [3.0]	
Rathke's Cleft, Cyst	1 [4.0]			
Thyroid Gland	(50)	(50)	(44)	(47)
C-cell, Hyperplasia	32 [1.2]	34 [1.3]	28 [1.1]	20 [1.1]
Follicle, Cyst				1 [2.0]
Follicular Cell, Hyperplasia	1 [1.0]			

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Epididymis	(50)	(50)	(50)	(49)
Fibrosis				1 [2.0]
Granuloma Sperm	2 [2.0]	2 [3.0]	2 [2.0]	2 [2.5]
Inflammation	1 [2.0]	1 [1.0]	1 [1.0]	2 [2.0]
Preputial Gland	(50)	(50)	(50)	(50)
Inflammation	9 [1.6]	14 [1.3]	13 [1.2]	8 [1.5]
Mineralization				1 [1.0]
Duct, Ectasia	3 [2.3]	1 [2.0]		1 [2.0]
Prostate	(50)	(50)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Atrophy			1 [2.0]	
Inflammation	9 [2.1]	11 [2.3]	10 [2.1]	3 [1.7]
Mineralization				1 [2.0]
Epithelium, Cyst			2 [2.0]	
Epithelium, Hyperplasia	15 [1.1]	6 [1.3]	12 [1.1]	3 [1.0]
Seminal Vesicle	(50)	(50)	(50)	(49)
Atrophy			1 [2.0]	
Inflammation		1 [2.0]		1 [2.0]
Mineralization				1 [2.0]
Epithelium, Hyperplasia			1 [2.0]	
Testes	(50)	(50)	(50)	(49)
Cyst	1 [4.0]			
Inflammation		1 [1.0]	2 [1.0]	
Mineralization				1 [2.0]
Germinal Epithelium, Atrophy	3 [2.3]	4 [2.5]	5 [2.4]	4 [3.0]
Interstitial Cell, Hyperplasia	1 [2.0]		2 [1.5]	1 [2.0]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	10 [3.1]	8 [3.0]	9 [2.0]	6 [2.8]
Lymph Node	(2)	(8)	(3)	(6)
Hematopoietic Cell Proliferation	1 [1.0]			
Deep Cervical, Hemorrhage				2 [2.5]
Mediastinal, Degeneration, Cystic		2 [3.5]		
Mediastinal, Hemorrhage				2 [2.5]
Mediastinal, Hyperplasia, Plasma Cell		3 [3.0]		
Mediastinal, Infiltration Cellular, Histiocyte				1 [2.0]
Pancreatic, Degeneration, Cystic				1 [2.0]
Pancreatic, Hemorrhage				1 [3.0]
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Degeneration, Cystic	1 [2.0]			
Fibrosis				2 [2.0]
Hemorrhage		1 [3.0]		1 [2.0]
Infiltration Cellular, Histiocyte			1 [2.0]	1 [2.0]
Mineralization				1 [2.0]
Spleen	(50)	(50)	(50)	(50)
Congestion			1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Depletion Cellular		1 [2.0]		
Fibrosis		2 [2.0]	1 [2.0]	
Hyperplasia, Lymphoid	3 [2.3]	2 [2.0]	2 [1.5]	
Hyperplasia, Reticulum Cell			1 [1.0]	
Infarct			1 [3.0]	
Thrombosis			1 [3.0]	
Lymphoid Follicle, Depletion Cellular			1 [3.0]	
Thymus	(50)	(48)	(48)	(47)
Atrophy			1 [3.0]	1 [4.0]
Ectopic Parathyroid Gland				1 [2.0]
Hemorrhage	1 [3.0]			
Inflammation		1 [2.0]		
Mineralization				1 [1.0]
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	1 [2.0]			
Inflammation	1 [2.0]			
Duct, Dilatation		1 [3.0]	3 [3.3]	
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion		6	1 [3.0]	1
Inflammation, Chronic Active	1 [3.0]	1 [2.0]		
Dermis, Fibrosis			1 [2.0]	
Hair Follicle, Cyst	1 [4.0]			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy			2 [3.0]	34 [2.3]
Skeletal Muscle	(0)	(0)	(1)	(0)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Hemorrhage		2 [2.5]	1 [3.0]	
Hydrocephalus		2 [1.5]		
Cerebrum, Compression			1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Cerebrum, Necrosis Meninges, Inflammation			1 [2.0]	1 [2.0]
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Congestion	2 [3.0]	1 [3.0]		
Edema			1 [2.0]	
Hemorrhage	1 [2.0]		1 [3.0]	1 [2.0]
Inflammation		1 [1.0]	1 [2.0]	
Inflammation, Chronic Active			1 [2.0]	
Metaplasia, Squamous	1 [1.0]			
Necrosis			1 [3.0]	
Alveolar Epithelium, Hyperplasia	11 [1.8]	9 [2.0]	11 [1.5]	11 [1.5]
Alveolus, Inflammation, Histiocyte				1 [1.0]
Alveolus, Inflammation, Histiocytic	27 [1.3]	35 [1.1]	37 [1.2]	36 [1.1]
Arteriole, Inflammation		1 [2.0]	1 [2.0]	
Arteriole, Necrosis			1 [2.0]	
Interstitial, Mineralization		1 [1.0]	2 [1.5]	16 [1.6]
Serosa, Hyperplasia	2 [2.0]			
Vein, Inflammation				1 [2.0]
Nose	(50)	(50)	(46)	(50)
Inflammation	25 [1.9]	23 [1.4]	30 [1.6]	28 [1.6]
Glands, Dilatation		2 [1.5]	1 [2.0]	1 [1.0]
Goblet Cell, Hyperplasia	3 [1.3]			
Olfactory Epithelium, Degeneration	1 [1.0]	5 [1.0]	33 [1.6]	19 [1.6]
Olfactory Epithelium, Metaplasia, Respiratory	2 [2.0]	3 [1.3]	6 [1.0]	
Respiratory Epithelium, Hyperplasia			1 [2.0]	
Turbinate, Inflammation			1 [2.0]	
Trachea	(50)	(50)	(50)	(50)
Inflammation	2 [1.0]	3 [1.0]	3 [1.0]	3 [1.3]
Peritracheal Tissue, Inflammation		1 [2.0]		
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Inflammation				3 [2.0]
Synechia				1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG Stop
Cornea, Inflammation				2 [1.5]
Harderian Gland	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell				1 [3.0]
Inflammation	2 [2.0]		2 [1.5]	
Epithelium, Hyperplasia	3 [2.3]		5 [2.4]	6 [2.0]
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Cyst			2 [2.5]	7 [2.1]
Glomerulopathy, Hyaline			9 [1.1]	24 [1.6]
Hydronephrosis		1 [2.0]		
Inflammation		1 [3.0]	2 [2.0]	
Nephropathy	45 [1.9]	45 [1.9]	50 [2.9]	50 [4.0]
Thrombosis			1 [3.0]	
Cortex, Mineralization	1 [1.0]	2 [1.0]	2 [1.5]	21 [2.1]
Pelvis, Dilatation	1 [2.0]			
Renal Tubule, Pigmentation	1 [3.0]			
Transitional Epithelium, Hyperplasia	1 [4.0]			
Urinary Bladder	(50)	(50)	(50)	(49)
Hemorrhage		1 [2.0]		
Inflammation	1 [1.0]	1 [2.0]		1 [3.0]
Ulcer		1 [3.0]		
Transitional Epithelium, Hyperplasia		1 [2.0]		

*** END OF MALE ***

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1		1
Moribund Sacrifice	13	8	7	29
Natural Death	6	4	5	20
Survivors				
Terminal Sacrifice	31	37	38	
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Inflammation		1 [2.0]		1 [1.0]
Muscularis, Degeneration		1 [1.0]		
Periesophageal Tissue, Inflammation		1 [4.0]		
Intestine Large, Cecum	(50)	(50)	(49)	(45)
Inflammation		1 [1.0]	3 [1.0]	12 [1.8]
Ulcer				1 [3.0]
Intestine Large, Colon	(50)	(50)	(49)	(45)
Inflammation				1 [1.0]
Mineralization				1 [2.0]
Parasite Metazoan	3	2		
Ulcer			1 [4.0]	
Intestine Large, Rectum	(50)	(50)	(50)	(49)
Erosion				1 [2.0]
Inflammation				1 [1.0]
Parasite Metazoan	4	6	7	1
Intestine Small, Ileum	(50)	(50)	(49)	(45)
Parasite Metazoan				1
Intestine Small, Jejunum	(50)	(50)	(49)	(45)
Peyer's Patch, Hyperplasia			1 [2.0]	
Liver	(50)	(50)	(50)	(47)
Angiectasis		5 [1.4]		
Basophilic Focus	44	21	3	2
Clear Cell Focus	8	12	4	1
Fatty Change	7 [1.3]	25 [1.4]	35 [1.9]	11 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Hepatodiaphragmatic Nodule	3	6	7	2
Inflammation	35 [1.2]	31 [1.1]	37 [1.5]	33 [1.2]
Mixed Cell Focus	5		4	
Bile Duct, Cyst	1 [3.0]	6 [2.3]	38 [2.3]	13 [1.8]
Bile Duct, Hyperplasia	5 [1.0]	4 [1.3]	49 [3.2]	43 [3.7]
Centrilobular, Hepatocyte, Degeneration		1 [2.0]		
Hepatocyte, Cellular Alteration, Diffuse		4 [2.0]	45 [1.5]	43 [1.9]
Hepatocyte, Necrosis	4 [1.5]	2 [1.5]	20 [1.7]	15 [2.0]
Hepatocyte, Regeneration				1 [3.0]
Oval Cell, Hyperplasia			45 [1.7]	43 [1.8]
Portal, Fibrosis		3 [1.0]	28 [1.3]	35 [1.4]
Serosa, Fibrosis			1 [2.0]	
Serosa, Hemorrhage			3 [3.0]	
Serosa, Inflammation			1 [2.0]	
Mesentery	(6)	(12)	(5)	(1)
Necrosis	5 [3.0]	12 [2.9]	5 [3.2]	1 [3.0]
Oral Mucosa	(1)	(0)	(0)	(2)
Pharyngeal, Hyperplasia	1 [3.0]			2 [2.0]
Pancreas	(50)	(50)	(49)	(46)
Atypia Cellular			1 [2.0]	
Basophilic Focus		1		
Inflammation			2 [2.0]	
Acinus, Atrophy	11 [1.4]	12 [1.2]	15 [1.1]	17 [1.5]
Acinus, Hyperplasia	7 [1.6]	1 [1.0]	1 [1.0]	2 [1.0]
Duct, Cyst	2 [1.5]	4 [1.0]	3 [1.0]	3 [1.0]
Salivary Glands	(50)	(50)	(50)	(49)
Inflammation	1 [1.0]		1 [1.0]	
Mineralization	1 [1.0]		1 [1.0]	
Stomach, Forestomach	(50)	(50)	(49)	(46)
Erosion		1 [3.0]		
Inflammation	3 [1.3]	3 [1.7]	7 [2.0]	3 [2.0]
Mineralization	1 [1.0]			
Ulcer	3 [2.0]	1 [3.0]	3 [2.7]	3 [2.7]
Epithelium, Hyperplasia	11 [2.0]	7 [2.1]	15 [2.0]	9 [1.7]
Stomach, Glandular	(50)	(50)	(49)	(46)
Erosion	1 [1.0]			3 [2.0]
Inflammation				1 [1.0]
Mineralization	1 [2.0]	3 [1.3]	1 [1.0]	13 [2.2]
Epithelium, Hyperplasia				1 [2.0]
Tongue	(0)	(1)	(1)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Tooth	(1)	(0)	(2)	(1)
Dysplasia			1 [4.0]	
Peridental Tissue, Inflammation			1 [2.0]	1 [2.0]
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Mineralization		1 [2.0]		20 [2.3]
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	48 [1.6]	45 [2.0]	47 [1.9]	44 [2.0]
Hypertrophy		1 [2.0]		1 [2.0]
Inflammation				4 [2.5]
Mineralization		1 [2.0]	1 [1.0]	11 [2.0]
Artery, Inflammation				1 [3.0]
Atrium, Thrombosis			1 [2.0]	1 [3.0]
Endocardium, Ventricle, Thrombosis				1 [3.0]
Valve, Thrombosis				1 [4.0]
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(49)
Degeneration, Cystic	1 [3.0]	4 [1.5]		
Hematopoietic Cell Proliferation		1 [2.0]		
Hemorrhage			1 [3.0]	
Hyperplasia	10 [1.5]	7 [1.4]	6 [1.3]	14 [1.5]
Hypertrophy	20 [1.6]	14 [1.6]	34 [1.6]	20 [1.6]
Adrenal Medulla	(50)	(50)	(50)	(49)
Hyperplasia	6 [1.2]	11 [1.1]	17 [1.6]	27 [1.7]
Mineralization	1 [1.0]			
Islets, Pancreatic	(50)	(50)	(49)	(46)
Parathyroid Gland	(46)	(47)	(49)	(49)
Cyst	1 [1.0]			
Hyperplasia		1 [1.0]	11 [2.0]	31 [2.9]
Pituitary Gland	(50)	(50)	(50)	(50)
Hemorrhage		2 [3.0]		1 [3.0]
Pars Distalis, Angiectasis			1 [2.0]	1 [2.0]
Pars Distalis, Cyst	4 [2.3]			1 [4.0]
Pars Distalis, Hyperplasia	17 [2.3]	26 [2.0]	24 [1.8]	12 [1.5]
Rathke's Cleft, Cyst	1 [4.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Thyroid Gland	(50)	(50)	(50)	(49)
Inflammation				1 [2.0]
C-cell, Hyperplasia	39 [1.3]	32 [1.2]	19 [1.1]	3 [1.0]
Follicle, Cyst	1 [2.0]	1 [3.0]	1 [3.0]	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(50)	(50)	(50)	(49)
Hyperplasia	3 [2.3]	1 [2.0]		1 [2.0]
Inflammation	6 [2.0]	7 [2.3]	1 [1.0]	3 [1.3]
Duct, Cyst	2 [2.0]	2 [3.0]	1 [3.0]	
Ovary	(50)	(50)	(49)	(46)
Atrophy	5 [1.2]	5 [2.2]	4 [2.8]	16 [2.3]
Cyst	6 [2.7]	4 [2.8]	5 [3.2]	5 [2.0]
Hemorrhage				1 [3.0]
Uterus	(50)	(50)	(50)	(47)
Hemorrhage	2 [3.5]	1 [3.0]		1 [3.0]
Hydrometra			1 [3.0]	3 [2.7]
Inflammation		1 [1.0]		2 [2.5]
Cervix, Cyst				1 [3.0]
Endometrium, Cyst		1 [2.0]		
Endometrium, Hyperplasia, Cystic	1 [3.0]	3 [2.0]	2 [2.0]	5 [1.8]
Vagina	(0)	(0)	(1)	(0)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemorrhage			2 [2.0]	
Hyperplasia	8 [3.1]	8 [3.3]	20 [3.0]	38 [2.9]
Infiltration Cellular, Histiocyte	1 [2.0]			
Myelofibrosis		1 [3.0]	1 [3.0]	
Lymph Node	(2)	(3)	(5)	(11)
Deep Cervical, Hemorrhage		1 [3.0]		3 [2.7]
Deep Cervical, Hyperplasia, Lymphoid			1 [2.0]	1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Deep Cervical, Hyperplasia, Plasma Cell	1 [2.0]			
Deep Cervical, Pigmentation, Hemosiderin			1 [2.0]	
Mediastinal, Degeneration, Cystic	1 [3.0]		1 [2.0]	
Mediastinal, Hemorrhage				2 [2.5]
Mediastinal, Hyperplasia, Plasma Cell			2 [3.0]	
Pancreatic, Hemorrhage				3 [2.7]
Pancreatic, Infiltration Cellular, Histiocyte			1 [3.0]	
Lymph Node, Mesenteric	(50)	(50)	(50)	(45)
Hemorrhage	2 [1.5]		1 [1.0]	18 [2.2]
Inflammation				2 [2.0]
Necrosis, Lymphoid				1 [2.0]
Spleen	(50)	(50)	(50)	(46)
Accessory Spleen		1		
Fibrosis			1 [2.0]	
Hematopoietic Cell Proliferation			1 [2.0]	2 [2.0]
Hemorrhage	1 [4.0]			1 [2.0]
Hyperplasia, Lymphoid	3 [2.7]		1 [2.0]	2 [2.0]
Necrosis, Lymphoid				1 [2.0]
Pigmentation, Hemosiderin		1 [2.0]		
Thrombosis	1 [3.0]			
Capsule, Hemorrhage			1 [4.0]	
Thymus	(50)	(49)	(47)	(47)
Atrophy	1 [2.0]			1 [3.0]
Cyst		1 [3.0]		
Ectopic Parathyroid Gland				1 [1.0]
Inflammation	1 [4.0]	1 [2.0]		
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(49)
Hyperplasia		2 [3.0]		
Inflammation			1 [1.0]	
Mineralization		1 [1.0]		
Duct, Dilatation	2 [3.0]	4 [3.5]	1 [4.0]	
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1			
Epidermis, Hyperplasia		1 [1.0]		
Hair Follicle, Atrophy				1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Subcutaneous Tissue, Inflammation		1 [4.0]		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy			1 [2.0]	27 [2.9]
Skeletal Muscle	(1)	(0)	(0)	(1)
Hemorrhage				1 [3.0]
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Hemorrhage	1 [2.0]		1 [4.0]	1 [4.0]
Hydrocephalus	2 [2.0]	1 [2.0]		
Thrombosis				1 [1.0]
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Bacterium				1
Congestion			1 [2.0]	
Hemorrhage				12 [2.4]
Inflammation	1 [1.0]	3 [2.0]		
Inflammation, Suppurative				1 [4.0]
Pigmentation, Hemosiderin				1 [2.0]
Thrombosis				1 [2.0]
Alveolar Epithelium, Hyperplasia	8 [1.5]	14 [1.4]	10 [1.1]	12 [1.3]
Alveolar Epithelium, Metaplasia, Squamous		1 [3.0]		
Alveolus, Inflammation, Histiocytic	40 [1.0]	44 [1.0]	49 [1.0]	43 [1.1]
Arteriole, Inflammation				2 [2.0]
Interstitial, Mineralization				16 [1.7]
Perivascular, Inflammation			1 [2.0]	
Serosa, Inflammation		1 [1.0]		
Nose	(50)	(50)	(50)	(41)
Inflammation	12 [1.3]	22 [1.7]	39 [2.2]	26 [2.5]
Thrombosis		1 [3.0]	2 [3.0]	2 [3.0]
Glands, Dilatation		6 [1.2]	6 [1.5]	2 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Olfactory Epithelium, Degeneration	2 [1.0]	40 [1.2]	48 [2.0]	37 [2.1]
Olfactory Epithelium, Metaplasia, Respiratory	1 [1.0]	8 [1.1]	46 [1.7]	36 [2.0]
Olfactory Epithelium, Necrosis				1 [2.0]
Respiratory Epithelium, Hyperplasia		1 [2.0]		
Respiratory Epithelium, Necrosis				1 [2.0]
Septum, Fibrosis			1 [3.0]	
Turbinates, Inflammation			1 [2.0]	
Trachea	(50)	(50)	(50)	(50)
Hemorrhage				1 [3.0]
Inflammation	5 [1.0]	1 [1.0]	1 [1.0]	3 [1.0]
Perforation				1 [4.0]
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Cataract	1 [3.0]	3 [3.0]	2 [3.5]	1 [2.0]
Hemorrhage				3 [3.7]
Inflammation	1 [3.0]	1 [1.0]		9 [2.3]
Optic Nerve, Atrophy				1 [2.0]
Retina, Atrophy	2 [3.0]	4 [3.8]	3 [3.7]	2 [2.0]
Retina, Dysplasia			2 [2.0]	
Harderian Gland	(50)	(50)	(50)	(50)
Inflammation		1 [1.0]		
Mineralization			1 [1.0]	
Epithelium, Hyperplasia			1 [3.0]	
Zymbal's Gland	(1)	(0)	(1)	(0)
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(49)
Angiectasis	1 [2.0]			
Cyst	2 [2.0]			2 [2.5]
Glomerulopathy, Hyaline		17 [1.0]	49 [2.2]	48 [3.3]
Glomerulosclerosis	1 [2.0]			
Hemorrhage	1 [2.0]			
Inflammation		1 [1.0]	1 [1.0]	2 [3.0]
Nephropathy	42 [1.2]	44 [1.3]	49 [2.9]	48 [3.4]
Cortex, Mineralization		1 [2.0]	1 [2.0]	26 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:57:45

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/09/03 / 04/10/03

Species/Strain: RATS/F 344/N

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	37.5 MG/KG	75.0 MG/KG	150 MG/KG Stop
Pelvis, Inflammation			1 [3.0]	
Renal Tubule, Degeneration		2 [2.0]		
Urinary Bladder	(50)	(49)	(50)	(47)
Inflammation	1 [1.0]			2 [1.5]
Transitional Epithelium, Hyperplasia			2 [1.0]	1 [1.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)